Skip to main content

Articles

Page 63 of 70

  1. Cancer induction after radiation therapy is known as a severe side effect. It is therefore of interest to predict the probability of second cancer appearance for the patient to be treated including breast cancer.

    Authors: Uwe Schneider, Marcin Sumila, Judith Robotka, Günther Gruber, Andreas Mack and Jürgen Besserer
    Citation: Radiation Oncology 2011 6:67
  2. The combined treatment modality of ionizing radiation (IR) with inhibitors of angiogenesis (IoA) is a promising treatment modality based on preclinical in vivo studies using heterotopic xeno- and allograft tumor ...

    Authors: Oliver Riesterer, Christoph Oehler-Jänne, Wolfram Jochum, Angela Broggini-Tenzer, Van Vuong and Martin Pruschy
    Citation: Radiation Oncology 2011 6:66
  3. In modern cancer medicine, morphological magnetic resonance imaging (MRI) is routinely used in diagnostics, treatment planning and assessment of therapeutic efficacy. During the past decade, functional imaging...

    Authors: Kathrine Røe, Manish Kakar, Therese Seierstad, Anne H Ree and Dag R Olsen
    Citation: Radiation Oncology 2011 6:65
  4. A strong dose-volume relationship exists between the amount of small bowel receiving low- to intermediate-doses of radiation and the rates of acute, severe gastrointestinal toxicity, principally diarrhea. Ther...

    Authors: Henry Mok, Christopher H Crane, Matthew B Palmer, Tina M Briere, Sam Beddar, Marc E Delclos, Sunil Krishnan and Prajnan Das
    Citation: Radiation Oncology 2011 6:63
  5. Different radiation-techniques in treating local staged prostate cancer differ in their dose- distribution. Physical phantom measurements indicate that for 3D, less healthy tissue is exposed to a relatively hi...

    Authors: Felix Zwicker, Benedict Swartman, Florian Sterzing, Gerald Major, Klaus-Josef Weber, Peter E Huber, Christian Thieke, Jürgen Debus and Klaus Herfarth
    Citation: Radiation Oncology 2011 6:62
  6. Biological models are used to relate the outcome of radiation therapy to dose distribution. As use of biological models in treatment planning expands, uncertainties associated with the use of specific models f...

    Authors: Vitali Moiseenko, William Y Song, Loren K Mell and Niranjan Bhandare
    Citation: Radiation Oncology 2011 6:61
  7. Either higher levels of initial DNA damage or lower levels of radiation-induced apoptosis in peripheral blood lymphocytes have been associated to increased risk for develop late radiation-induced toxicity. It ...

    Authors: Luis Alberto Henríquez-Hernández, Ruth Carmona-Vigo, Beatriz Pinar, Elisa Bordón, Marta Lloret, María Isabel Núñez, Carlos Rodríguez-Gallego and Pedro C Lara
    Citation: Radiation Oncology 2011 6:60
  8. Radiotherapy and radiology have been indispensable components in cancer care for many years. The detection limit of small tumor foci as well as the development of radio-resistance and severe side effects towar...

    Authors: Thomas Efferth and Peter Langguth
    Citation: Radiation Oncology 2011 6:59
  9. Hearing loss is common following chemoradiotherapy for children with medulloblastoma. Compared to photons, proton radiotherapy reduces radiation dose to the cochlea for these patients. Here we examine whether ...

    Authors: Benjamin J Moeller, Murali Chintagumpala, Jimmy J Philip, David R Grosshans, Mary F McAleer, Shiao Y Woo, Paul W Gidley, Tribhawan S Vats and Anita Mahajan
    Citation: Radiation Oncology 2011 6:58
  10. This work aimed to investigate the effect of costunolide, a sesquiterpene lactone isolated from Michelia compressa, on cell cycle distribution and radiosensitivity of human hepatocellular carcinoma (HCC) cells.

    Authors: Chia-Yuan Liu, Hsun-Shuo Chang, Ih-Sheng Chen, Chih-Jen Chen, Ming-Ling Hsu, Shu-Ling Fu and Yu-Jen Chen
    Citation: Radiation Oncology 2011 6:56
  11. Since the 1980s major advances in surgery, radiotherapy and chemotherapy have established multimodal approaches as curative treatment options for oesophageal cancer. In addition the introduction of functional ...

    Authors: Maria C Wolf, Michael Stahl, Bernd J Krause, Luigi Bonavina, Christiane Bruns, Claus Belka and Franz Zehentmayr
    Citation: Radiation Oncology 2011 6:55
  12. To establish recurrence patterns among locally advanced head and neck non-nasopharyngeal squamous cell carcinoma (HNSCC) patients treated with radical (chemo-) radiotherapy and to correlate the sites of loco-r...

    Authors: Didem C Oksuz, Robin J Prestwich, Brendan Carey, Stuart Wilson, Mustafa S Senocak, Ananya Choudhury, Karen Dyker, Catherine Coyle and Mehmet Sen
    Citation: Radiation Oncology 2011 6:54
  13. To evaluate prognostic factors that may influence local control (LC) of T1N0 glottic cancer treated by primary radiotherapy (RT) with 6 MV photons.

    Authors: Chi-Chung Tong, Kwok-Hung Au, Roger KC Ngan, Sin-Ming Chow, Foon-Yiu Cheung, Yiu-Tung Fu, Joseph SK Au and Stephen CK Law
    Citation: Radiation Oncology 2011 6:53
  14. To evaluate the palliative role of radiotherapy (RT) and define the effectiveness of chemotherapy combined with palliative RT (CCRT) in patients with a symptomatic pelvic mass of metastatic colorectal cancer.

    Authors: Sun Hyun Bae, Won Park, Doo Ho Choi, Heerim Nam, Won Ki Kang, Young Suk Park, Joon Oh Park, Ho Kyung Chun, Woo Yong Lee, Seong Hyeon Yun and Hee Cheol Kim
    Citation: Radiation Oncology 2011 6:52
  15. To assess the clinical outcome of chemoradiotherapy with or without surgery for locally recurrent rectal cancer (LRRC) and to find useful and significant prognostic factors for a clinical situation.

    Authors: Joo Ho Lee, Dae Yong Kim, Sun Young Kim, Ji Won Park, Hyo Seong Choi, Jae Hwan Oh, Hee Jin Chang, Tae Hyun Kim and Suk Won Park
    Citation: Radiation Oncology 2011 6:51
  16. Although preoperative radiotherapy (RT) is widely used as the initial treatment for locally advanced rectal cancer (RC) in the neoadjuvant setting, factors determining clinical response have not been adequatel...

    Authors: Koji Yasuda, Takako Nirei, Eiji Sunami, Hirokazu Nagawa and Joji Kitayama
    Citation: Radiation Oncology 2011 6:49
  17. to investigate the factors affecting survival and toxicity in patients treated with stereotactic radiosurgery (SRS), with special attention to volumes of brain receiving a specific dose (V10 - V16 Gy) as predi...

    Authors: Giuseppe Minniti, Enrico Clarke, Gaetano Lanzetta, Mattia Falchetto Osti, Guido Trasimeni, Alessandro Bozzao, Andrea Romano and Riccardo Maurizi Enrici
    Citation: Radiation Oncology 2011 6:48
  18. Radiation enteritis is a significant complication of external beam radiotherapy (EBRT) to the pelvis, particularly in patients having high dose radiotherapy (>80 Gy) and in those with a low pelvic peritoneal r...

    Authors: Gary D McKay, Karen Wong and Daniel R Kozman
    Citation: Radiation Oncology 2011 6:47
  19. At present there is no consensus on irradiation treatment volumes for intermediate to high-risk primary cancers or recurrent disease. Conventional imaging modalities, such as CT, MRI and transrectal ultrasound...

    Authors: Florian Würschmidt, Cordula Petersen, Andreas Wahl, Jörg Dahle and Matthias Kretschmer
    Citation: Radiation Oncology 2011 6:44
  20. To assess the value of diffusion weighted imaging (DWI) as an early surrogate parameter for treatment response of colorectal liver metastases to image-guided single-fraction 192Ir-high-dose-rate brachytherapy (HD...

    Authors: Christian Wybranski, Martin Zeile, David Löwenthal, Frank Fischbach, Maciej Pech, Friedrich-Wilhelm Röhl, Günther Gademann, Jens Ricke and Oliver Dudeck
    Citation: Radiation Oncology 2011 6:43
  21. Gene expression profiling of the transcriptional response of human dermal fibroblasts to in vitro radiation has shown promise as a predictive test of radiosensitivity. This study tested if treatment with the radi...

    Authors: Charlotte B Westbury, Kristine Kleivi Sahlberg, Anne-Lise Borresen-Dale, Clare M Isacke and John R Yarnold
    Citation: Radiation Oncology 2011 6:42
  22. Olfactory Neuroblastoma is a rare malignant tumor of the olfactory tract. Reports in the literature comparing treatment modalities for this tumor are limited.

    Authors: Mary E Platek, Mihai Merzianu, Terry L Mashtare, Saurin R Popat, Nestor R Rigual, Graham W Warren and Anurag K Singh
    Citation: Radiation Oncology 2011 6:41
  23. Hepatic radiation toxicity restricts irradiation of liver malignancies. Better knowledge of hepatic tolerance dose is favourable to gain higher safety and to optimize radiation regimes in radiotherapy of the l...

    Authors: Max Seidensticker, Ricarda Seidensticker, Konrad Mohnike, Christian Wybranski, Thomas Kalinski, Sebastian Luess, Maciej Pech, Peter Wust and Jens Ricke
    Citation: Radiation Oncology 2011 6:40
  24. Perifosine is a membrane-targeted alkylphospholipid developed to inhibit the PI3K/Akt pathway and has been suggested as a favorable candidate for combined use with radiotherapy. In this study, we investigated ...

    Authors: Yuanhong Gao, Hiromichi Ishiyama, Mianen Sun, Kathryn L Brinkman, Xiaozhen Wang, Julie Zhu, Weiyuan Mai, Ying Huang, Daniel Floryk, Michael Ittmann, Timothy C Thompson, E Brian Butler, Bo Xu and Bin S Teh
    Citation: Radiation Oncology 2011 6:39
  25. The purpose of this study is to investigate intra-fraction setup variability in hypo-fractionated cranial and body radiotherapy; this is achieved by means of integrated infrared optical localization and stereo...

    Authors: Maria Francesca Spadea, Barbara Tagaste, Marco Riboldi, Eleonora Preve, Daniela Alterio, Gaia Piperno, Cristina Garibaldi, Roberto Orecchia, Antonio Pedotti and Guido Baroni
    Citation: Radiation Oncology 2011 6:38
  26. In the quest of a curative radiotherapy treatment for gliomas new delivery modes are being explored. At the Biomedical Beamline of the European Synchrotron Radiation Facility (ESRF), a new spatially-fractionat...

    Authors: Silvia Gil, Sukhéna Sarun, Albert Biete, Yolanda Prezado and Manel Sabés
    Citation: Radiation Oncology 2011 6:37
  27. Oxygen deficiency in tumor tissue is associated with a malign phenotype, characterized by high invasiveness, increased metastatic potential and poor prognosis. Hypoxia chambers are the established standard mod...

    Authors: Vasileios Askoxylakis, Gunda Millonig, Ute Wirkner, Christian Schwager, Shoaib Rana, Annette Altmann, Uwe Haberkorn, Jürgen Debus, Sebastian Mueller and Peter E Huber
    Citation: Radiation Oncology 2011 6:35
  28. Melanoma and renal cell carcinoma (RCC) are traditionally considered less radioresponsive than other histologies. Whereas stereotactic body radiation therapy (SBRT) involves radiation dose intensification via ...

    Authors: Michelle A Stinauer, Brian D Kavanagh, Tracey E Schefter, Rene Gonzalez, Thomas Flaig, Karl Lewis, William Robinson, Mark Chidel, Michael Glode and David Raben
    Citation: Radiation Oncology 2011 6:34
  29. In early-phase studies with targeted therapeutics and radiotherapy, it may be difficult to decide whether an adverse event should be considered a dose-limiting toxicity (DLT) of the investigational systemic ag...

    Authors: Ã…se Bratland, Svein Dueland, Donal Hollywood, Kjersti Flatmark and Anne H Ree
    Citation: Radiation Oncology 2011 6:33
  30. Radiotherapists are highly interested in optimizing doses especially for patients who tend to suffer from side effects of radiotherapy (RT). It seems to be helpful to identify radiosensitive individuals before...

    Authors: Reinhard Huber, Herbert Braselmann, Hans Geinitz, Irene Jaehnert, Adolf Baumgartner, Reinhard Thamm, Markus Figel, Michael Molls and Horst Zitzelsberger
    Citation: Radiation Oncology 2011 6:32
  31. The study of lung parenchyma anatomical modification is useful to estimate dose discrepancies during the radiation treatment of Non-Small-Cell Lung Cancer (NSCLC) patients. We propose and validate a method, ba...

    Authors: Elena Faggiano, Giovanni M Cattaneo, Cristina Ciavarro, Italo Dell'Oca, Diego Persano, Riccardo Calandrino and Giovanna Rizzo
    Citation: Radiation Oncology 2011 6:31
  32. To evaluate feasibility and toxicity of carbon ion therapy for treatment of sinonasal malignancies. First site of treatment failure in malignant tumours of the paranasal sinuses and nasal cavity is mostly in-f...

    Authors: Alexandra D Jensen, Anna V Nikoghosyan, Swantje Ecker, Malte Ellerbrock, Jürgen Debus and Marc W Münter
    Citation: Radiation Oncology 2011 6:30
  33. MicroRNAs are regulators of central cellular processes and are implicated in the pathogenesis and prognosis of human cancers. MicroRNAs also modulate responses to anti-cancer therapy. In the context of radiati...

    Authors: Olivier M Niemoeller, Maximilian Niyazi, Stefanie Corradini, Franz Zehentmayr, Minglun Li, Kirsten Lauber and Claus Belka
    Citation: Radiation Oncology 2011 6:29
  34. We aimed to evaluate retrospectively the correlation of loco-regional relapse (LRR) rate, distant metastasis (DM) rate, disease free survival (DFS) and overall survival (OS) in a group of breast cancer (BC) pa...

    Authors: Rusen Cosar, Cem Uzal, Fusun Tokatli, Bengu Denizli, Mert Saynak, Nesrin Turan, Sernaz Uzunoglu, Alaattin Ozen, Atakan Sezer, Kamuran Ibis, Burcu Uregen, Vuslat Yurut-Caloglu and Zafer Kocak
    Citation: Radiation Oncology 2011 6:28
  35. This study evaluates the dose distribution of reversed planned tangential beam intensity modulated radiotherapy (IMRT) compared to standard wedged tangential beam three-dimensionally planned conformal radiothe...

    Authors: Volker Rudat, Abdul Aziz Alaradi, Adel Mohamed, Khaled AI-Yahya and Saleh Altuwaijri
    Citation: Radiation Oncology 2011 6:26
  36. There is little data on the safety of combining radiation therapy and human immunodeficiency virus (HIV) protease inhibitors to treat cancers in HIV-positive patients. We describe acute toxicities observed in ...

    Authors: Alfred P See, Jing Zeng, Phuoc T Tran and Michael Lim
    Citation: Radiation Oncology 2011 6:25
  37. Prognostic indexes are useful to guide tailored treatment strategies for cancer patients with brain metastasis (BM). We evaluated the new Graded Prognostic Assessment (GPA) scale in a prospective validation st...

    Authors: Salvador Villà, Damien C Weber, Cristina Moretones, Anabel Mañes, Christophe Combescure, Josep Jové, Paloma Puyalto, Patricia Cuadras, Jordi Bruna, Eugènia Verger, Carme Balañà and Francesc Graus
    Citation: Radiation Oncology 2011 6:23
  38. To report our experience with intensity-modulated or stereotactic reirradiation in patients suffering from recurrent nasopharyngeal carcinoma

    Authors: Falk Roeder, Felix Zwicker, Ladan Saleh-Ebrahimi, Carmen Timke, Christian Thieke, Marc Bischof, Juergen Debus and Peter E Huber
    Citation: Radiation Oncology 2011 6:22
  39. To verify the dose distribution and number of monitor units (MU) for dynamic treatment techniques like volumetric modulated single arc radiation therapy - Rapid Arc - each patient treatment plan has to be veri...

    Authors: Daniela Wagner and Hilke Vorwerk
    Citation: Radiation Oncology 2011 6:21
  40. Recent developments enable to deliver rotational IMRT with standard C-arm gantry based linear accelerators. This upcoming treatment technique was benchmarked in a multi-center treatment planning study against ...

    Authors: Tilo Wiezorek, Tim Brachwitz, Dietmar Georg, Eyck Blank, Irina Fotina, Gregor Habl, Matthias Kretschmer, Gerd Lutters, Henning Salz, Kai Schubert, Daniela Wagner and Thomas G Wendt
    Citation: Radiation Oncology 2011 6:20
  41. Sensorineural hearing loss (SNHL) is one of the major long term side effects from radiation therapy (RT) in nasopharyngeal cancer (NPC) patients. This study aims to review the incidences of SNHL when treating ...

    Authors: Janjira Petsuksiri, Achariyaporn Sermsree, Kullathorn Thephamongkhol, Phawin Keskool, Kanthong Thongyai, Yaowalak Chansilpa and Pittayapoom Pattaranutaporn
    Citation: Radiation Oncology 2011 6:19
  42. This phase I study investigates the feasibility of carboplatin plus dose-dense (q2-week) pemetrexed given concurrently with radiotherapy (XRT) for locally advanced and oligometastatic non-small cell lung cance...

    Authors: Xinglei Shen, Albert DeNittis, Maria Werner-Wasik, Rita Axelrod, Paul Gilman, Thomas Meyer, Joseph Treat, Walter J Curran and Mitchell Machtay
    Citation: Radiation Oncology 2011 6:17

Annual Journal Metrics

  • 2022 Citation Impact
    3.6 - 2-year Impact Factor
    3.8 - 5-year Impact Factor
    1.370 - SNIP (Source Normalized Impact per Paper)
    1.037 - SJR (SCImago Journal Rank)

    2023 Speed
    16 days submission to first editorial decision for all manuscripts (Median)
    132 days submission to accept (Median)

    2023 Usage 
    1,958,690 downloads
    605 Altmetric mentions